查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601252

RNA 治療市場：按技術、適應症和最終用戶分類 - 全球預測 2025-2030

RNA Therapy Market by Technology (Enabled Technologies, Enabling Technologies), Indication (Cancer, Cardiovascular, Genetic Disorders), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

RNA治療市場2023年估值為21.8億美元，預計2024年將達26億美元，複合年成長率為22.38%，預計到2030年將達到89.8億美元。

RNA療法是生物技術和製藥行業的前沿領域，專注於利用RNA分子治療各種疾病。這種創新方法包括RNA干擾(RNAi)、反義寡核苷酸 (ASO) 和傳訊RNA(mRNA) 療法，它們透過標靶和操縱遺傳物質發揮作用。對 RNA 療法的需求源於其治療傳統小分子和蛋白質治療方法難以解決的疾病的潛力，包括需要精確基因校正的遺傳疾病、癌症，預計將應用於罕見疾病。 RNA 療法的最終用途和應用正在擴大，在藥物發現、臨床試驗和個人化醫療方面進行了大量投資。關鍵的成長要素包括遞送技術的進步、對 RNA 機制的更好理解以及有利的法律規範。 RNA 治療市場的最新潛在創新機會在於改善遞送系統、擴大治療標靶以及開發具有成本效益的製造流程。透過專注於與學術機構和生物技術公司的夥伴關係和合作，可以進一步加速創新。然而，遞送功效、免疫抗原性問題和高開發成本等挑戰以及監管障礙和市場競爭是主要限制因素。成熟的創新領域包括基於奈米顆粒的遞送系統以及探索新型 RNA 修飾技術以提高穩定性並最大限度地減少脫靶效應。由於基因組學和生物技術的快速發展，市場格局充滿活力，並以研發活動頻繁的競爭環境為特徵。為了利用不斷變化的機會，相關人員應強調多學科合作，整合人工智慧主導的藥物發現，並投資可擴展的生產技術以提高市場滲透率。對於希望利用 RNA 療法進步的光明未來的公司來說，解決這些因素至關重要。

主要市場統計
基準年[2023] 21.8億美元
預測年份 [2024] 26億美元
預測年份 [2030] 89.8億美元
複合年成長率（%） 22.38%

市場動態：揭示快速發展的 RNA 治療市場的關鍵市場洞察

RNA 治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 人們對 RNA 在疾病病理學中的作用有了越來越多的了解
    • 個人化醫療需求不斷成長
    • 透過與製藥公司的策略聯盟促進新RNA療法的開發
  • 市場限制因素
    • RNA 療法開發過程相關的高成本
  • 市場機會
    • 政府和私人機構增加對研發活動的投資
    • 基於 RNA 的管道療法的臨床試驗
  • 市場挑戰
    • RNA分子的不穩定性質和嚴格的監管準則所帶來的問題

波特五力：駕馭 RNA 治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 RNA 治療市場的外部影響

外部宏觀環境因素在塑造 RNA 治療市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解RNA治療市場的競爭狀況

RNA 治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位基質 RNA 治療市場供應商績效評估

FPNV定位矩陣是評估RNA治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 加深我們對 RNA 在疾病病理學中作用的理解
      • 個人化醫療需求不斷成長
      • 透過與製藥公司的策略聯盟促進新藥開發
    • 抑制因素
      • RNA 療法開發過程相關的高成本
    • 機會
      • 政府和私人組織增加對研發活動的投資
      • 基於 RNA 的療法的臨床試驗管道
    • 任務
      • RNA分子不穩定引起的問題和嚴格的監管指南
  • 市場區隔分析
    • 技術：對推動 RNA 治療進步的技術的需求不斷成長。
    • 適應症：RNA療法在遺傳和癌症疾病的廣泛應用。
    • 最終用戶：專注於推動診斷和藥物開發的新發現的學術研究變得越來越重要。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章 RNA 治療市場：依技術分類

  • 使能技術
    • 抑制
    • 標籤
    • 線性擴增
    • 微陣列
    • 精製
    • 定量RT-PCR
  • 實行技術
    • RNA反義技術
      • 微型RNA
      • 小干擾RNA
    • RNA干擾技術

第7章 RNA 治療市場（按適應症）

  • 癌症
  • 心血管
  • 遺傳疾病
  • 感染疾病
  • 腎臟疾病
  • 代謝紊亂
  • 腫瘤學
  • 視網膜疾病

第8章 RNA 治療市場：依最終使用者分類

  • 學術研究
  • 診斷
  • 藥物發現與開發

第9章美洲RNA治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太RNA治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的RNA治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • ADARx Pharmaceuticals 是下一代 RNA 療法的領導者，宣布超額認購 2 億美元 C 輪資金籌措
    • ReNAgade Therapeutics 斥資 3 億美元進軍 RNA 治療領域
    • Esperovax 和 Gingo Bioworks 宣布合作開發基於環狀 RNA 的療法

公司名單

  • Arbutus Biopharma Corporation
  • NeuBase Therapeutics, Inc.
  • Moderna, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • AstraZeneca PLC
  • Arrowhead Pharmaceuticals, Inc.
  • Nordic Nanovector ASA
  • MiNA Therapeutics Limited
  • Silence Therapeutics PLC
  • Eli Lilly and Company
  • Cartesian Therapeutics, Inc.
  • Novartis AG
  • Sirnaomics, Inc.
  • F. Hoffmann-La Roche AG
  • ProQR Therapeutics NV
  • Cenix BioScience GmbH
  • Nutcracker Therapeutics, Inc.
  • Laronde
  • Triplet Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Deep Genomics
  • Biogen Inc.
  • GSK PLC
  • Benitec Biopharma Limited
  • Sanofi SA
  • Novo Nordisk A/S
Product Code: MRR-0375F3EAA7E7

The RNA Therapy Market was valued at USD 2.18 billion in 2023, expected to reach USD 2.60 billion in 2024, and is projected to grow at a CAGR of 22.38%, to USD 8.98 billion by 2030.

RNA therapy represents a cutting-edge segment of the biotechnology and pharmaceutical industries, focusing on the use of RNA molecules to treat a variety of diseases. This innovative approach includes RNA interference (RNAi), antisense oligonucleotides (ASOs), and messenger RNA (mRNA) therapies, which operate by targeting and manipulating genetic material. The necessity of RNA therapies is driven by their potential to treat conditions that are difficult to address with traditional small molecule and protein-based therapies, offering promise for genetic disorders, cancer, and rare diseases where precise genetic correction is crucial. The application and end-use scope of RNA therapy are expanding, with significant investments in drug discovery, clinical trials, and personalized medicine. Key growth factors include advancements in delivery technologies, increasing understanding of RNA mechanisms, and favorable regulatory frameworks. The latest potential opportunities in RNA therapy market innovation lie in refining delivery systems, expanding therapeutic targets, and developing cost-effective manufacturing processes. A focus on partnerships and collaborations with academic institutions and biotech companies could further accelerate innovation. However, challenges such as delivery efficacy, immunogenicity issues, and high development costs pose significant limitations, alongside regulatory hurdles and market competition. Areas ripe for innovation include nanoparticle-based delivery systems and the exploration of novel RNA modification techniques to enhance stability and minimize off-target effects. Given the rapid pace of advancements in genomics and biotechnology, the RNA therapy market is dynamic, characterized by a competitive landscape with a high degree of research and development activity. To capitalize on the evolving opportunities, stakeholders should emphasize interdisciplinary collaboration, integrate AI-driven drug discovery, and invest in scalable production technologies to enhance market penetration. Addressing these factors will be crucial for businesses aiming to capitalize on the promising future of RNA therapeutic advancements.

KEY MARKET STATISTICS
Base Year [2023] USD 2.18 billion
Estimated Year [2024] USD 2.60 billion
Forecast Year [2030] USD 8.98 billion
CAGR (%) 22.38%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving RNA Therapy Market

The RNA Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing understanding of the role of RNA in disease pathology
    • Heightened demand for personalized medicine
    • Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
  • Market Restraints
    • High costs associated with RNA therapy development processes
  • Market Opportunities
    • Increased investments by governments and private organizations in research and development activities
    • Pipelined clinical trials of RNA-based therapeutics
  • Market Challenges
    • Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines

Porter's Five Forces: A Strategic Tool for Navigating the RNA Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the RNA Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the RNA Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the RNA Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the RNA Therapy Market

A detailed market share analysis in the RNA Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the RNA Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the RNA Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Arbutus Biopharma Corporation, NeuBase Therapeutics, Inc., Moderna, Inc., Arcturus Therapeutics Holdings Inc., BioNTech SE, AstraZeneca PLC, Arrowhead Pharmaceuticals, Inc., Nordic Nanovector ASA, MiNA Therapeutics Limited, Silence Therapeutics PLC, Eli Lilly and Company, Cartesian Therapeutics, Inc., Novartis AG, Sirnaomics, Inc., F. Hoffmann-La Roche AG, ProQR Therapeutics N.V., Cenix BioScience GmbH, Nutcracker Therapeutics, Inc., Laronde, Triplet Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Deep Genomics, Biogen Inc., GSK PLC, Benitec Biopharma Limited, Sanofi S.A., and Novo Nordisk A/S.

Market Segmentation & Coverage

This research report categorizes the RNA Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Enabled Technologies and Enabling Technologies. The Enabled Technologies is further studied across Inhibition, Labeling, Linear amplification, Microarrays, Purification, and qRT-PCR. The Enabling Technologies is further studied across RNA Antisense Technologies and RNA Interference Technologies. The RNA Antisense Technologies is further studied across MicroRNA and Small interfering RNA.
  • Based on Indication, market is studied across Cancer, Cardiovascular, Genetic Disorders, Infectious Diseases, Kidney Diseases, Metabolic Disorders, Oncology, and Retinal Diseases.
  • Based on End User, market is studied across Academic Research, Diagnostics, and Drug Discovery & Development.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing understanding of the role of RNA in disease pathology
      • 5.1.1.2. Heightened demand for personalized medicine
      • 5.1.1.3. Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with RNA therapy development processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased investments by governments and private organizations in research and development activities
      • 5.1.3.2. Pipelined clinical trials of RNA-based therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.
    • 5.2.2. Indication: Widespread applications of RNA therapy in genetic and cancer diseases.
    • 5.2.3. End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. RNA Therapy Market, by Technology

  • 6.1. Introduction
  • 6.2. Enabled Technologies
    • 6.2.1. Inhibition
    • 6.2.2. Labeling
    • 6.2.3. Linear amplification
    • 6.2.4. Microarrays
    • 6.2.5. Purification
    • 6.2.6. qRT-PCR
  • 6.3. Enabling Technologies
    • 6.3.1. RNA Antisense Technologies
      • 6.3.1.1. MicroRNA
      • 6.3.1.2. Small interfering RNA
    • 6.3.2. RNA Interference Technologies

7. RNA Therapy Market, by Indication

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Cardiovascular
  • 7.4. Genetic Disorders
  • 7.5. Infectious Diseases
  • 7.6. Kidney Diseases
  • 7.7. Metabolic Disorders
  • 7.8. Oncology
  • 7.9. Retinal Diseases

8. RNA Therapy Market, by End User

  • 8.1. Introduction
  • 8.2. Academic Research
  • 8.3. Diagnostics
  • 8.4. Drug Discovery & Development

9. Americas RNA Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific RNA Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa RNA Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing
    • 12.3.2. ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million
    • 12.3.3. Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

Companies Mentioned

  • 1. Arbutus Biopharma Corporation
  • 2. NeuBase Therapeutics, Inc.
  • 3. Moderna, Inc.
  • 4. Arcturus Therapeutics Holdings Inc.
  • 5. BioNTech SE
  • 6. AstraZeneca PLC
  • 7. Arrowhead Pharmaceuticals, Inc.
  • 8. Nordic Nanovector ASA
  • 9. MiNA Therapeutics Limited
  • 10. Silence Therapeutics PLC
  • 11. Eli Lilly and Company
  • 12. Cartesian Therapeutics, Inc.
  • 13. Novartis AG
  • 14. Sirnaomics, Inc.
  • 15. F. Hoffmann-La Roche AG
  • 16. ProQR Therapeutics N.V.
  • 17. Cenix BioScience GmbH
  • 18. Nutcracker Therapeutics, Inc.
  • 19. Laronde
  • 20. Triplet Therapeutics, Inc.
  • 21. Ionis Pharmaceuticals, Inc.
  • 22. Alnylam Pharmaceuticals, Inc.
  • 23. Deep Genomics
  • 24. Biogen Inc.
  • 25. GSK PLC
  • 26. Benitec Biopharma Limited
  • 27. Sanofi S.A.
  • 28. Novo Nordisk A/S

LIST OF FIGURES

  • FIGURE 1. RNA THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. RNA THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RNA THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RNA THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INHIBITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY LABELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY LINEAR AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY QRT-PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY MICRORNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY RNA INTERFERENCE TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY RETINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 287. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023